Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain RARE message board posts where the ticker symbol RARE has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest RARE SEC Filings

Filings Format Description Filing Date File/Film Number
8-K  Documents Current report, item 5.07
Acc-no: 0001564590-18-015905 (34 Act)  Size: 53 KB
2018-06-21 001-36276
18910669
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-038873 Size: 4 KB
2018-06-20
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-038861 Size: 7 KB
2018-06-20
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-038859 Size: 7 KB
2018-06-20
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-038857 Size: 7 KB
2018-06-20
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-038852 Size: 7 KB
2018-06-20
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-038844 Size: 7 KB
2018-06-20
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-038835 Size: 7 KB
2018-06-20
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-038831 Size: 7 KB
2018-06-20
4  Documents Statement of changes in beneficial ownership of securities
Acc-no: 0001209191-18-038210 Size: 8 KB
2018-06-15
More RARE SEC Filings


Related news from
Tue, 19 Jun 2018
11:30:00 +0000
Report: Developing Opportunities within Spartan Motors, Ultragenyx Pharmaceutical, Advanced Energy Industries, Verisk Analytics, Cogent Communications, and ADTRAN — Future Expectations, Projections Moving into 2018
NEW YORK, June 19, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Spartan ...
Thu, 14 Jun 2018
16:33:00 +0000
Why Biotech Stocks May Reach New Highs
Biotech stocks are nearing a big break out as measured by the SPDR S&P Biotech ETF ( XBI). The group is already having a strong start to 2018, quietly outpacing not only the S&P 500 but the most talked about sectors in the market, technology ( XLK) and consumer stocks ( XLY). The biotech ETF is sitting right below a significant resistance level at $97.90, the previous all-time high for the ETF, and should that price rise above technical resistance, it would mark a big breakout.
Thu, 07 Jun 2018
11:35:00 +0000
Today's Free Research Reports Coverage on Seattle Genetics and Three More Biotech Stocks
On Wednesday, June 06, 2018, US markets saw broad based gains with eight out of nine sectors finishing the trading sessions in green. All you have to do is sign up today for this free limited time offer by clicking the link below.
Mon, 04 Jun 2018
20:05:00 +0000
Ultragenyx to Present at Upcoming Investor Conferences
Jayson Dallas, M.D., the company’s Chief Commercial Officer, will present at the Jefferies 2018 Global Healthcare Conference on Tuesday, June 5, 2018 at 3:00 pm ET in New York. Emil D. Kakkis, M.D., Ph.D., the company's Chief Executive Officer, will present at the Goldman Sachs 39th Annual Global Healthcare Conference on Wednesday, June 13, 2018 at 2:40 pm PT in Rancho Palos Verdes, CA.
Tue, 29 May 2018
12:20:00 +0000
Today’s Research Reports on Stocks to Watch: Ultragenyx Pharmaceutical and BioMarin Pharmaceutical
NEW YORK, NY / ACCESSWIRE / May 29, 2018 / Ultragenyx Pharma shares jumped after announcing its clinical trial results for Crysvita® ( burosumab), while BioMarin Pharma earned approval for its Palynziq™ ...
Thu, 24 May 2018
12:37:35 +0000
Benzinga's Daily Biotech Pulse: Eiger And Melinta Fall On Offerings, Apellis And Marinus Rise On Bullish Ratings
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on May 23) ABIOMED, Inc. (NASDAQ: ABMD ) ArQule, Inc. (NASDAQ: ARQL ) Crispr ...
Wed, 23 May 2018
21:01:00 +0000
Ultragenyx and Kyowa Kirin Announce Publication of Phase 2 Study Results Demonstrating that Crysvita® (burosumab) Improved Outcomes in Children with X-linked Hypophosphatemia in the New England Journal of Medicine
Ultragenyx Pharmaceutical Inc. (RARE), Kyowa Hakko Kirin Co. Ltd, and Kyowa Kirin International PLC today announced that the results of a pediatric Phase 2 clinical trial of Crysvita® (burosumab) for the treatment of X-linked hypophosphatemia (XLH) in children aged 5 to 12 years were published online by the New England Journal of Medicine (NEJM). The results demonstrated that Crysvita improved rickets severity, growth, pain and physical function, and increased serum phosphorus and renal phosphate reabsorption.
Thu, 17 May 2018
12:30:00 +0000
Ultragenyx and Kyowa Kirin Announce Topline Phase 3 Study Results Demonstrating Superiority of Crysvita® (burosumab) Treatment to Oral Phosphate and Active Vitamin D in Children with X-Linked Hypophosphatemia (XLH)
Ultragenyx Pharmaceutical Inc. (RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, Kyowa Hakko Kirin Co. Ltd (Kyowa Hakko Kirin), and Kyowa Kirin International PLC (Kyowa Kirin International) today announced that the Phase 3 study of Crysvita® (burosumab) met its primary endpoint demonstrating that Crysvita was superior to oral phosphate and active vitamin D (conventional therapy) in improving rickets in children with X-linked hypophosphatemia (XLH) after 40 weeks of treatment (LS Mean treatment difference  of +1.14, p<0.0001). The study also showed improvement in important metabolic and functional measures with Crysvita treatment, and a safety profile similar to that observed in other Crysvita pediatric XLH studies.
Thu, 10 May 2018
07:46:24 +0000
Edited Transcript of RARE earnings conference call or presentation 7-May-18 9:00pm GMT
Q1 2018 Ultragenyx Pharmaceutical Inc Earnings Call
Mon, 07 May 2018
20:26:21 +0000
Ultragenyx: 1Q Earnings Snapshot
The Novato, California-based company said it had profit of 62 cents per share. The results beat Wall Street expectations. The average estimate of 12 analysts surveyed by Zacks Investment Research was for ...
Mon, 07 May 2018
20:05:00 +0000
Ultragenyx Reports First Quarter 2018 Financial Results and Corporate Update
Ultragenyx Pharmaceutical Inc. (RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today reported its financial results and corporate update for the quarter ended March 31, 2018. “With the recent approvals and launches of Crysvita in the United States and Europe, we have transformed into a commercial stage company with two medicines now available for patients,” said Emil D. Kakkis, M.D., Ph.D., Chief Executive Officer and President of Ultragenyx. For the first quarter of 2018, Ultragenyx reported net income of $30.3 million, or $0.63 per basic share and $0.62 per diluted share, compared with a net loss for the first quarter of 2017 of $68.3 million, or $1.63 per share, basic and diluted.
Mon, 07 May 2018
16:30:00 +0000
Ultragenyx Pharmaceutical, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / May 7, 2018 / Ultragenyx Pharmaceutical, Inc. (NASDAQ: RARE) will be discussing their earnings results in their Q1 Earnings Call to be held on May 7, 2018 at 5:00 PM Eastern ...
Tue, 01 May 2018
12:30:00 +0000
Ultragenyx to Host Conference Call for First Quarter 2018 Financial Results and Corporate Update
NOVATO, Calif., May 01, 2018-- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that it will host ...
Mon, 30 Apr 2018
12:30:00 +0000
Ultragenyx and Kyowa Kirin Announce Crysvita® (burosumab-twza) Now Launched in the U.S. for the Treatment of X–linked Hypophosphatemia (XLH) in Children and Adults
Ultragenyx Pharmaceutical Inc. (RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, Kyowa Hakko Kirin Co. Ltd, (Kyowa Hakko Kirin), and Kyowa Kirin International PLC (Kyowa Kirin International) today announced that Crysvita® (burosumab-twza) entered the commercial supply chain in the United States and generated its first sales to specialty pharmacies on April 27, 2018—ten days after its approval by the U.S. Food and Drug Administration (FDA). Crysvita was approved by the FDA for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients one year of age and older.
Wed, 25 Apr 2018
12:10:00 +0000
Investor Expectations to Drive Momentum within MicroStrategy, Marcus & Millichap, Gentex, Ultragenyx Pharmaceutical, Dave & Buster's Entertainment, and Glatfelter — Discovering Underlying Factors of Influence
NEW YORK, April 25, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
Mon, 23 Apr 2018
12:30:00 +0000
Ultragenyx Announces Filing and FDA Clearance of an Investigational New Drug Application for DTX401, a Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia
NOVATO, Calif., April 23, 2018-- Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that the U.S. ...
Wed, 18 Apr 2018
18:19:00 +0000
Ultragenyx Pharmaceutical Wins Approval for Drug Treating Rare Form of Rickets
Ultragenyx scored its second FDA drug approval in six months. The orphan disease specialist also picked up its second Rare Pediatric Disease Priority Review Voucher; its first sold for $130 million.
Wed, 18 Apr 2018
15:14:25 +0000
2 Bay Area drug approvals in 1 day underscore industry's issues, opportunities
Pricing and the wear and tear of years of clinical trials remain issues for the drug-development industry.
Tue, 17 Apr 2018
19:19:00 +0000
Ultragenyx and Kyowa Kirin Announce FDA Approval of Crysvita® (burosumab-twza) for the Treatment of Children and Adults with X-Linked Hypophosphatemia (XLH)
Ultragenyx Pharmaceutical Inc. (RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, Kyowa Hakko Kirin Co. Ltd (Kyowa Hakko Kirin), and Kyowa Kirin International PLC (Kyowa Kirin International) today announced that the U.S. Food and Drug Administration (FDA) has approved Crysvita® (burosumab-twza) for the treatment of X-linked hypophosphatemia (XLH) in adult and paediatric patients one year of age and older. Crysvita is an antibody that blocks fibroblast growth factor 23 (FGF23), a hormone that causes phosphate urinary excretion and suppresses active vitamin D production by the kidney.



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "ValueForum has been the most valuable tool I have ever come across when it comes to managing my investments. I can honestly say that the information shared on ValueForum has led me to retire earlier than expected. This is a wonderful investment site, period." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2018, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards